Tactile Systems Technology said it reeled in a $10.4 million Series B round led by Radius Ventures, with the proceeds to go toward acquiring "a leading new product" and patents for treating lymphedema, or fluid retention.
EnteroMedics Inc.
The weight loss pacemaker: MassDevice Q&A with EnteroMedics
EnteroMedics (NSDQ:ETRM) is looking to control metabolic disease by attacking the problem closer to its source – human behavior.
Weight loss: EnteroMedics gains on $75M stock offering
Minnesota-based EnteroMedics (NSDQ:ETRM) is looking to raise up to $75 million through sales of stock, securities and warrants, a move that gained the company some love from Wall Street.
Stryker to begin New York layoffs ahead of the medical device tax | Wall Street Beat
Rep. Paulsen expects device tax repeal on the House floor this week (video) | MassDevice.com On Call
MASSDEVICE ON CALL — Rep. Erik Paulsen’s long-running effort to repeal the medical device excise tax is nearing a climax in the House, the Congressman said during a recent episode of his regular "Correspondence Corner" videos.
Before answering questions sent by his constituents, Paulsen gave a shout out to Minnesota medical device makers and said he expects his tax repeal bill to get a House vote this week.
Zimmer slides on Q1 results | Earnings Roundup
Gingrich’s health consulting group goes under | Wall Street Beat
The Center for Health Transformation, a health care think tank launched by GOP presidential hopeful Newt Gingrich, filed for Chapter 7 bankruptcy this week, listing liabilities of between $1 million and $10 million that it says it can’t repay.
The organization’s assets, which it listed in court filings at between $50,000 and $100,000, will be liquidated and the business may subsequently close.
New FDA rules imperil Bioject | Wall Street Beat
Breast implants: FDA clears new silicon implant despite consumer protests | Regulatory Roundup
3M touts record sales and earnings per share for 2011 | Earnings Roundup
3M Co. (NYSE:MMM) beat expectations for its 4th-quarter profits and affirmed its guidance for 2012, but Wall Street remained unmoved, with shares staying flat in this morning’s trading.
Boston Scientific touts CMS reimbursement nod for asthma treatment | Regulatory Roundup
Boston Scientific Corp.’s (NYSE:BSX) Alair asthma management system won reimbursement from the Centers for Medicare & Medicaid Services, effective at the start of this year.
The Alair system delivers precise thermal energy lung to tissue via bronchoscope to reduce excessively smooth muscle, decreasing the airway’s ability to constrict.